1
|
Tiefenbrunner I, Brutiu BR, Stopka T, Maulide N. Isothiouronium-Mediated Conversion of Carboxylic Acids to Cyanomethyl Thioesters. J Org Chem 2023; 88:3941-3944. [PMID: 36853206 PMCID: PMC10028607 DOI: 10.1021/acs.joc.2c02902] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/01/2023]
Abstract
We report the development of an isothiouronium salt as a reagent for the operationally simple synthesis of cyanomethyl thioesters with high functional group tolerance and avoiding the use of thiols. Additionally, we show that the products can be engaged in amide synthesis in either a two-step or one-pot fashion.
Collapse
Affiliation(s)
| | - Bogdan R Brutiu
- Institute of Organic Chemistry, University of Vienna, 1090 Vienna Austria
| | - Tobias Stopka
- Institute of Organic Chemistry, University of Vienna, 1090 Vienna Austria
| | - Nuno Maulide
- Institute of Organic Chemistry, University of Vienna, 1090 Vienna Austria
| |
Collapse
|
2
|
Zemanova Z, Brezinova J, Svobodova K, Lhotska H, Aghova T, Vidlakova D, Izakova S, Lizcova L, Ransdorfova S, Mendlikova I, Pavlistova L, Belickova M, Vesela J, Siskova M, Neuwirtova R, Cermak J, Stopka T, Jonasova A. Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations. Leuk Res 2021. [DOI: 10.1016/j.leukres.2021.106681.22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
3
|
Merad J, Matyašovský J, Stopka T, Brutiu BR, Pinto A, Drescher M, Maulide N. Stable and easily available sulfide surrogates allow a stereoselective activation of alcohols. Chem Sci 2021; 12:7770-7774. [PMID: 34168830 PMCID: PMC8188487 DOI: 10.1039/d1sc01602d] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Isothiouronium salts are easily accessible and stable compounds. Herein, we report their use as versatile deoxasulfenylating agents enabling a stereoselective, thiol-free protocol for synthesis of thioethers from alcohols. The method is simple, scalable and tolerates a broad range of functional groups otherwise incompatible with other methods. Late-stage modification of several pharmaceuticals provides access to multiple analogues of biologically relevant molecules. Performed experiments give insight into the reaction mechanism. A simple and scalable method for stereoselective synthesis of thioethers directly from alcohols using isothiouronium salts is presented. The utility of this thiol-free reaction was exemplified by late-stage modification of complex molecules.![]()
Collapse
Affiliation(s)
- Jérémy Merad
- Department of Organic Chemistry, University of Vienna Währinger Straße 38 1090 Vienna Austria http://maulide.univie.ac.at.,Univ. Lyon, Université Claude Bernard Lyon 1, CNRS CPE Lyon, INSA Lyon, ICBMS, UMR 5246 Bât. Lederer 1 rue Victor Grignard 69622 Villeurbanne France
| | - Ján Matyašovský
- Department of Organic Chemistry, University of Vienna Währinger Straße 38 1090 Vienna Austria http://maulide.univie.ac.at
| | - Tobias Stopka
- Department of Organic Chemistry, University of Vienna Währinger Straße 38 1090 Vienna Austria http://maulide.univie.ac.at
| | - Bogdan R Brutiu
- Department of Organic Chemistry, University of Vienna Währinger Straße 38 1090 Vienna Austria http://maulide.univie.ac.at
| | - Alexandre Pinto
- Department of Organic Chemistry, University of Vienna Währinger Straße 38 1090 Vienna Austria http://maulide.univie.ac.at
| | - Martina Drescher
- Department of Organic Chemistry, University of Vienna Währinger Straße 38 1090 Vienna Austria http://maulide.univie.ac.at
| | - Nuno Maulide
- Department of Organic Chemistry, University of Vienna Währinger Straße 38 1090 Vienna Austria http://maulide.univie.ac.at
| |
Collapse
|
4
|
|
5
|
Minarik L, Vargova K, Dusilkova N, Kulvait V, Jonasova A, Kodet O, Stopka T. Hereditary Haemorrhagic Telangiectasia (HHT) Marked by ACVRL1C1120T Variant Displays Hypopigmented Naevi and Frequent Bleeding Episodes if CYP2C9 Co-Mutated: Clinical Notes & Rationale of Patient Registry. Folia Biol (Praha) 2020; 66:1-6. [PMID: 32512653] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
Hereditary haemorrhagic telangiectasia (HHT) exhibits considerable phenotypic heterogeneity. Therefore, precise mutation screening and evaluation of patient risk must be determined in every HHT family. We present an HHT-2 case with an initial life-threatening bleeding episode that led to identification of a relatively large HHT family. Exome sequencing of the family members determined HHT-associated ACVRL1C1120T variant resulting in Arg374Trp substitution at the Ser/Thr-kinase domain region. The affected members display typical epistaxis symptomatology from early childhood resulting in sideropoenia. In addition, the HHT patients also displayed dermatology findings such as facial teleangiectasias and trunk/limb white spots representing post-inflammatory hypopigmentation. Interestingly, co-segregating with modifying cytochrome P450 (CYP2C) variant in the HHT patients led to NSAID intolerance marked by increased frequency of bleeding episodes. No arterial-venous malformation of the visceral organs and brain or association with cancer were observed. The heterogeneity of clinical presentation and the role of other variants support the need of regular patient monitoring and development of a nation-wide patient registry.
Collapse
Affiliation(s)
- L Minarik
- Biocev, First Faculty of Medicine, Charles University, Vestec, Czech Republic
| | - K Vargova
- Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - N Dusilkova
- Biocev, First Faculty of Medicine, Charles University, Vestec, Czech Republic
- Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - V Kulvait
- Biocev, First Faculty of Medicine, Charles University, Vestec, Czech Republic
| | - A Jonasova
- First Department of Medicine, Department of Haematology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
| | - O Kodet
- Department of Dermatology and Venereology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
| | - T Stopka
- Biocev, First Faculty of Medicine, Charles University, Vestec, Czech Republic
- First Department of Medicine, Department of Haematology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
| |
Collapse
|
6
|
Stopka T, Adler P, Hagn G, Zhang H, Tona V, Maulide N. Electrophilic Activation of Amides for the Preparation of Polysubstituted Pyrimidines. SYNTHESIS-STUTTGART 2018. [DOI: 10.1055/s-0037-1610411] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
In this article we describe the straightforward synthesis of polysubstituted pyrimidines by electrophilic activation of secondary amides in the presence of alkynes. An unusual mechanistic detour leading to pyridine derivatives as products is also presented and briefly discussed.
Collapse
Affiliation(s)
| | | | | | | | | | - Nuno Maulide
- University of Vienna, Institute of Organic Chemistry
| |
Collapse
|
7
|
Sochor M, Bašová P, Pešta M, Bartoš J, Stopka T. Prediction potential of serum miR-155 and miR-24 for relapsing early breast cancer. Eur J Cancer 2018. [DOI: 10.1016/s0959-8049(18)30585-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
8
|
Huskova H, Ardin M, Weninger A, Vargova K, Barrin S, Villar S, Olivier M, Stopka T, Herceg Z, Hollstein M, Zavadil J, Korenjak M. Modeling cancer driver events in vitro using barrier bypass-clonal expansion assays and massively parallel sequencing. Oncogene 2017; 36:6041-6048. [PMID: 28692054 PMCID: PMC5666318 DOI: 10.1038/onc.2017.215] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2016] [Revised: 03/30/2017] [Accepted: 05/12/2017] [Indexed: 12/14/2022]
Abstract
The information on candidate cancer driver alterations available from public databases is often descriptive and of limited mechanistic insight, which poses difficulties for reliable distinction between true driver and passenger events. To address this challenge, we performed in-depth analysis of whole-exome sequencing data from cell lines generated by a barrier bypass-clonal expansion (BBCE) protocol. The employed strategy is based on carcinogen-driven immortalization of primary mouse embryonic fibroblasts and recapitulates early steps of cell transformation. Among the mutated genes were almost 200 COSMIC Cancer Gene Census genes, many of which were recurrently affected in the set of 25 immortalized cell lines. The alterations affected pathways regulating DNA damage response and repair, transcription and chromatin structure, cell cycle and cell death, as well as developmental pathways. The functional impact of the mutations was strongly supported by the manifestation of several known cancer hotspot mutations among the identified alterations. We identified a new set of genes encoding subunits of the BAF chromatin remodeling complex that exhibited Ras-mediated dependence on PRC2 histone methyltransferase activity, a finding that is similar to what has been observed for other BAF subunits in cancer cells. Among the affected BAF complex subunits, we determined Smarcd2 and Smarcc1 as putative driver candidates not yet fully identified by large-scale cancer genome sequencing projects. In addition, Ep400 displayed characteristics of a driver gene in that it showed a mutually exclusive mutation pattern when compared with mutations in the Trrap subunit of the TIP60 complex, both in the cell line panel and in a human tumor data set. We propose that the information generated by deep sequencing of the BBCE cell lines coupled with phenotypic analysis of the mutant cells can yield mechanistic insights into driver events relevant to human cancer development.
Collapse
Affiliation(s)
- H Huskova
- Molecular Mechanisms and Biomarkers Group, International Agency for Research on Cancer, Lyon, France
- Biocev, First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - M Ardin
- Molecular Mechanisms and Biomarkers Group, International Agency for Research on Cancer, Lyon, France
| | - A Weninger
- Deutsches Krebsforschungszentrum, Heidelberg, Germany
| | - K Vargova
- Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - S Barrin
- Dynamics of T cell Interactions Team, Institut Cochin, Inserm U1016, Paris, France
| | - S Villar
- Molecular Mechanisms and Biomarkers Group, International Agency for Research on Cancer, Lyon, France
| | - M Olivier
- Molecular Mechanisms and Biomarkers Group, International Agency for Research on Cancer, Lyon, France
| | - T Stopka
- Biocev, First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Z Herceg
- Epigenetics Group, International Agency for Research on Cancer, Lyon, France
| | - M Hollstein
- Molecular Mechanisms and Biomarkers Group, International Agency for Research on Cancer, Lyon, France
- Deutsches Krebsforschungszentrum, Heidelberg, Germany
- Faculty of Medicine and Health, University of Leeds, LIGHT Laboratories, Leeds, UK
| | - J Zavadil
- Molecular Mechanisms and Biomarkers Group, International Agency for Research on Cancer, Lyon, France
| | - M Korenjak
- Molecular Mechanisms and Biomarkers Group, International Agency for Research on Cancer, Lyon, France
| |
Collapse
|
9
|
Abstract
The selective, metal-free generation of α-carbonyl cations from simple internal alkynes was accomplished by the addition of a sulfoxide to a densely substituted vinyl cation. The high reactivity of the α-carbonyl cations was found to efficiently induce hydrogen and even carbon shift reactions with unusual selecivities. Complex compounds with highly congested tertiary and all-carbon-substituted quartenary carbon centers can thus be accessed in a single step from simple precursors. Mechanistic analysis strongly supports the intermediacy of the title compounds and provides a simple predictive scheme for the migratory aptitude of different substituents.
Collapse
Affiliation(s)
- Tobias Stopka
- Institute of Organic Chemistry, RWTH Aachen University, Landoltweg 1, 52074, Aachen, Germany
| | - Meike Niggemann
- Institute of Organic Chemistry, RWTH Aachen University, Landoltweg 1, 52074, Aachen, Germany
| | - Nuno Maulide
- Institute of Organic Chemistry, University of Vienna, Währinger Strasse 38, 1090, Vienna, Austria
| |
Collapse
|
10
|
Affiliation(s)
- Tobias Stopka
- Institut für Organische Chemie; RWTH Aachen Universität; Landoltweg 1 52074 Aachen Deutschland
| | - Meike Niggemann
- Institut für Organische Chemie; RWTH Aachen Universität; Landoltweg 1 52074 Aachen Deutschland
| | - Nuno Maulide
- Institut für Organische Chemie; Universität Wien; Währinger Straße 38 1090 Wien Österreich
| |
Collapse
|
11
|
Vargova K, Pesta M, Obrtlikova P, Dusilkova N, Minarik L, Vargova J, Berkova A, Zemanova Z, Michalova K, Spacek M, Trneny M, Stopka T. MiR-155/miR-150 network regulates progression through the disease phases of chronic lymphocytic leukemia. Blood Cancer J 2017; 7:e585. [PMID: 28731457 PMCID: PMC5549255 DOI: 10.1038/bcj.2017.63] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Affiliation(s)
- K Vargova
- Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - M Pesta
- Department of Probability and Mathematical Statistics, Faculty of Mathematics and Physics, Charles University, Prague, Czech Republic
| | - P Obrtlikova
- First Internal Clinic, Department of Hematology, First Faculty of Medicine and General Hospital, Charles University, Prague, Czech Republic
| | - N Dusilkova
- Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.,Department Biocev, First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - L Minarik
- First Internal Clinic, Department of Hematology, First Faculty of Medicine and General Hospital, Charles University, Prague, Czech Republic.,Department Biocev, First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - J Vargova
- Department Biocev, First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - A Berkova
- Department of Cytogenetics, First Faculty of Medicine and General Hospital, Charles University, Prague, Czech Republic
| | - Z Zemanova
- Department of Cytogenetics, First Faculty of Medicine and General Hospital, Charles University, Prague, Czech Republic
| | - K Michalova
- Department of Cytogenetics, First Faculty of Medicine and General Hospital, Charles University, Prague, Czech Republic
| | - M Spacek
- First Internal Clinic, Department of Hematology, First Faculty of Medicine and General Hospital, Charles University, Prague, Czech Republic
| | - M Trneny
- First Internal Clinic, Department of Hematology, First Faculty of Medicine and General Hospital, Charles University, Prague, Czech Republic
| | - T Stopka
- First Internal Clinic, Department of Hematology, First Faculty of Medicine and General Hospital, Charles University, Prague, Czech Republic.,Department Biocev, First Faculty of Medicine, Charles University, Prague, Czech Republic
| |
Collapse
|
12
|
Fuchs O, Polak J, Bokorova R, Kostecka A, Vostry M, Neuwirtova R, Siskova M, Stopka T, Lauermannova M, Maaloufova JS, Salek C, Mikulenkova D, Cermak J, Brezinova J, Zemanova Z, Michalova K, Jonasova A. High Level of Full-Length Cereblon Messenger RNA and Protein is Important for Lenalidomide Efficacy in Lower Risk MDS Patients. Leuk Res 2017. [DOI: 10.1016/s0145-2126(17)30340-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
13
|
Polgarova K, Kulvait V, Vargova K, Minarik L, Dusilkova N, Zemanova Z, Jonasova A, Stopka T. Tracking of the Somatic Mutations in MDS Patients During Disease Restaging Improves Prediction of Oncoming Relapse or Disease Progression. Leuk Res 2017. [DOI: 10.1016/s0145-2126(17)30201-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
14
|
Zemanova Z, Michalova K, Brezinova J, Svobodova K, Lhotska H, Sarova I, Lizcova L, Izakova S, Ransdorfova S, Pavlistova L, Berkova A, Skipalova K, Belickova M, Siskova M, Neuwirtova R, Cermak J, Stopka T, Jonasova A. Cytogenetic Clonal Evolution in Myelodysplastic Syndromes (MDS) with Isolated Del(5Q). Leuk Res 2017. [DOI: 10.1016/s0145-2126(17)30203-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
15
|
Vargova J, Vargova K, Dusilkova N, Kulvait V, Pospisil V, Zavadil J, Trneny M, Klener P, Stopka T. Differential expression, localization and activity of MARCKS between mantle cell lymphoma and chronic lymphocytic leukemia. Blood Cancer J 2016; 6:e475. [PMID: 27662204 PMCID: PMC5056972 DOI: 10.1038/bcj.2016.80] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Affiliation(s)
- J Vargova
- Biocev, First Faculty of Medicine, Charles University, Vestec, Czech Republic
| | - K Vargova
- Biocev, First Faculty of Medicine, Charles University, Vestec, Czech Republic
| | - N Dusilkova
- Biocev, First Faculty of Medicine, Charles University, Vestec, Czech Republic
| | - V Kulvait
- Biocev, First Faculty of Medicine, Charles University, Vestec, Czech Republic
| | - V Pospisil
- Biocev, First Faculty of Medicine, Charles University, Vestec, Czech Republic
| | - J Zavadil
- Group of Molecular Mechanisms and Biomarkers, International Agency for Research on Cancer, Lyon, France
| | - M Trneny
- Department of Hematology, General Faculty Hospital, Prague, Czech Republic
| | - P Klener
- Department of Hematology, General Faculty Hospital, Prague, Czech Republic
| | - T Stopka
- Biocev, First Faculty of Medicine, Charles University, Vestec, Czech Republic
- Department of Hematology, General Faculty Hospital, Prague, Czech Republic
| |
Collapse
|
16
|
Abstract
A synergistic Brønsted acid catalyst was used to intermolecularly generate vinyl cations for a C–C bond formation – Schmidt rearrangement – sequence.
Collapse
Affiliation(s)
- T. Stopka
- Institute of Organic Chemistry
- RWTH Aachen University
- 52074 Aachen
- Germany
| | - M. Niggemann
- Institute of Organic Chemistry
- RWTH Aachen University
- 52074 Aachen
- Germany
| |
Collapse
|
17
|
Affiliation(s)
- Shuang Gao
- Institute of Organic Chemistry, RWTH Aachen University, 52074 Aachen, Germany
| | - Tobias Stopka
- Institute of Organic Chemistry, RWTH Aachen University, 52074 Aachen, Germany
| | - Meike Niggemann
- Institute of Organic Chemistry, RWTH Aachen University, 52074 Aachen, Germany
| |
Collapse
|
18
|
Stopka T, Vargova K, Kulvait V, Vargova J, Dusilkova N, Jonasova A. 277 ASXL1 GENE MUTATIONS ACCUMULATE IN AZACITIDINE-TREATED MDS PATIENTS AND ASSOCIATE WITH ADVERSE PROGNOSIS. Leuk Res 2015. [DOI: 10.1016/s0145-2126(15)30278-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
19
|
Stopka T, Niggemann M. Cyclopentanone as a Cation-Stabilizing Electron-Pair Donor in the Calcium-Catalyzed Intermolecular Carbohydroxylation of Alkynes. Org Lett 2015; 17:1437-40. [DOI: 10.1021/acs.orglett.5b00312] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Tobias Stopka
- Institute of Organic Chemistry, RWTH Aachen University, 52074 Aachen, Germany
| | - Meike Niggemann
- Institute of Organic Chemistry, RWTH Aachen University, 52074 Aachen, Germany
| |
Collapse
|
20
|
Stopka T, Marzo L, Zurro M, Janich S, Würthwein EU, Daniliuc CG, Alemán J, Mancheño OG. Oxidative CH Bond Functionalization and Ring Expansion with TMSCHN2: A Copper(I)-Catalyzed Approach to Dibenzoxepines and Dibenzoazepines. Angew Chem Int Ed Engl 2015; 54:5049-53. [DOI: 10.1002/anie.201411726] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2014] [Indexed: 12/14/2022]
|
21
|
Basova P, Pospisil V, Savvulidi F, Burda P, Vargova K, Stanek L, Dluhosova M, Kuzmova E, Jonasova A, Steidl U, Laslo P, Stopka T. Aggressive acute myeloid leukemia in PU.1/p53 double-mutant mice. Oncogene 2013; 33:4735-45. [PMID: 24121269 DOI: 10.1038/onc.2013.414] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2013] [Revised: 08/23/2013] [Accepted: 09/02/2013] [Indexed: 01/02/2023]
Abstract
PU.1 downregulation within hematopoietic stem and progenitor cells (HSPCs) is the primary mechanism for the development of acute myeloid leukemia (AML) in mice with homozygous deletion of the upstream regulatory element (URE) of PU.1 gene. p53 is a well-known tumor suppressor that is often mutated in human hematologic malignancies including AML and adds to their aggressiveness; however, its genetic deletion does not cause AML in mouse. Deletion of p53 in the PU.1(ure/ure) mice (PU.1(ure/ure)p53(-/-)) results in more aggressive AML with shortened overall survival. PU.1(ure/ure)p53(-/-) progenitors express significantly lower PU.1 levels. In addition to URE deletion we searched for other mechanisms that in the absence of p53 contribute to decreased PU.1 levels in PU.1(ure/ure)p53(-/-) mice. We found involvement of Myb and miR-155 in downregulation of PU.1 in aggressive murine AML. Upon inhibition of either Myb or miR-155 in vitro the AML progenitors restore PU.1 levels and lose leukemic cell growth similarly to PU.1 rescue. The MYB/miR-155/PU.1 axis is a target of p53 and is activated early after p53 loss as indicated by transient p53 knockdown. Furthermore, deregulation of both MYB and miR-155 coupled with PU.1 downregulation was observed in human AML, suggesting that MYB/miR-155/PU.1 mechanism may be involved in the pathogenesis of AML and its aggressiveness characterized by p53 mutation.
Collapse
Affiliation(s)
- P Basova
- 1] Department of Pathophysiology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic [2] Department of Experimental Biomodels, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
| | - V Pospisil
- Department of Pathophysiology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
| | - F Savvulidi
- Department of Pathophysiology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
| | - P Burda
- Department of Pathophysiology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
| | - K Vargova
- Department of Pathophysiology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
| | - L Stanek
- 1] Department of Pathophysiology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic [2] Department of Pathology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
| | - M Dluhosova
- Department of Pathophysiology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
| | - E Kuzmova
- Department of Pathophysiology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
| | - A Jonasova
- 1] Department of Pathophysiology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic [2] Department of Medicine-Haematology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
| | - U Steidl
- Albert Einstein College of Medicine, Yeshiva University, Bronx, NY, USA
| | - P Laslo
- Section of Experimental Haematology, Leeds Institute of Cancer and Pathology, St James's University Hospital, University of Leeds, Leeds, UK
| | - T Stopka
- 1] Department of Pathophysiology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic [2] Department of Medicine-Haematology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
| |
Collapse
|
22
|
Rohlmann R, Stopka T, Richter H, Garcı́a Mancheño O. Iron-Catalyzed Oxidative Tandem Reactions with TEMPO Oxoammonium Salts: Synthesis of Dihydroquinazolines and Quinolines. J Org Chem 2013; 78:6050-64. [DOI: 10.1021/jo4007199] [Citation(s) in RCA: 120] [Impact Index Per Article: 10.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Affiliation(s)
- Renate Rohlmann
- Organisch-Chemisches
Institut, Westfälische Wilhelms-Universität Münster, Corrensstrasse 40, 48149 Münster,
Germany
| | - Tobias Stopka
- Organisch-Chemisches
Institut, Westfälische Wilhelms-Universität Münster, Corrensstrasse 40, 48149 Münster,
Germany
| | - Heinrich Richter
- Organisch-Chemisches
Institut, Westfälische Wilhelms-Universität Münster, Corrensstrasse 40, 48149 Münster,
Germany
| | - Olga Garcı́a Mancheño
- Organisch-Chemisches
Institut, Westfälische Wilhelms-Universität Münster, Corrensstrasse 40, 48149 Münster,
Germany
| |
Collapse
|
23
|
|
24
|
Stopka T, Curik N, Burda P, Vargova K, Pospisil V, Hajkova H, Sawulidi F, Necas E, Belickova M, Haskovec C, Cermak J, Trneny M, Jonasova A. 52 Chromatin structure at PU.l gene and cell differentiation capacity in myelodysplastic syndrome treated by 5-azacytidine. Leuk Res 2011. [DOI: 10.1016/s0145-2126(11)70054-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
25
|
Plasilova M, Zivny J, Jelinek J, Neuwirtova R, Cermak J, Necas E, Andera L, Stopka T. TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors. Leukemia 2002; 16:67-73. [PMID: 11840265 DOI: 10.1038/sj.leu.2402338] [Citation(s) in RCA: 89] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2001] [Accepted: 08/29/2001] [Indexed: 11/09/2022]
Abstract
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL, APO2L) has been shown to induce apoptosis in a number of tumor cell lines as well as in some primary tumors whereas cells from most normal tissues are highly resistant to TRAIL-induced apoptosis. We have studied the susceptibility of primary malignant and normal bone marrow hematopoietic progenitors to TRAIL-induced apoptosis. Extracellular domain of human TRAIL with N-terminal His(6) tag (His-TRAIL, amino acids 95-281) was produced in E. coli and its apoptosis-inducing ability was compared with the leucine-zipper containing TRAIL, LZ-TRAIL. Both variants of TRAIL had the same apoptosis-inducing ability. Clonogenic progenitor assays showed that His-TRAIL significantly reduced the number of myeloid colonies (CFU-GM) and clusters from patients with acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and myelodysplastic syndromes (MDS). His-TRAIL had no negative effect on the number of CFU-GM colonies and clusters derived from bone marrow cells of AML patients in complete remission, and lymphoma patients without bone marrow involvement, as well as those derived from normal cord blood cells. Moreover, we found that normal human stem cells treated with high doses of His-TRAIL maintain a repopulating potential when transplanted into NOD/SCID mice. To conclude, our data document that TRAIL does not affect normal human hematopoiesis but suppresses the growth of early primary leukemia and myelodysplasia progenitors.
Collapse
Affiliation(s)
- M Plasilova
- Institute of Hematology and Blood Transfusion, Prague, Czech Republic
| | | | | | | | | | | | | | | |
Collapse
|
26
|
Pomyje J, Zivný JH, Stopka T, Simák J, Vanková H, Necas E. Angiopoietin-1, angiopoietin-2 and Tie-2 in tumour and non-tumour tissues during growth of experimental melanoma. Melanoma Res 2001; 11:639-43. [PMID: 11725211 DOI: 10.1097/00008390-200112000-00011] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Tumour progression is dependent on the formation of new vessels in tumour tissue. Tumour cells produce a variety of factors that influence vessel growth and maintenance both in tumour and tumour-adjacent tissues. Angiopoietin-1 (Ang-1), angiopoietin-2 (Ang-2) and their tyrosine kinase receptor Tie-2 have been shown to play an important role in the processes of growth and remodelling of normal as well as tumour vessels. We studied gene expression of the angiogenic factors Ang-1 and Ang-2 and of their tyrosine kinase receptor Tie-2 in the tumour and non-tumour tissues of mice bearing the experimental melanoma B16. Using semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) and real-time PCR we measured Ang-1, Ang-2 and Tie-2 mRNA levels in the tumour, bone marrow, liver and spleen. Melanoma tissue overexpressed Ang-2 mRNA compared with spleen, liver and bone marrow of normal mice, suggesting its role during melanoma progression. On the other hand, there was a significant decrease in Ang-2 mRNA level in bone marrow cells collected on days 5 and 10 of tumour growth compared with the expression of Ang-2 mRNA in the bone marrow of normal mice and those collected on days 15 and 20 of tumour growth. These data demonstrate, for the first time, an ectopic effect of the tumour on the gene coding for an angiogenic factor, and also suggest that tumour growth may influence angiogenesis and/or vasculogenesis in distant organs.
Collapse
Affiliation(s)
- J Pomyje
- Department of Pathophysiology, 1st Medical Faculty, Charles University Prague, Czech Republic
| | | | | | | | | | | |
Collapse
|
27
|
Cmejla R, Blafkova J, Stopka T, Jelinek J, Petrtylova K, Pospisilova D. Ribosomal proteins S3a, S13, S16, and S24 are not mutated in patients with Diamond-Blackfan anemia. Blood 2001; 97:579-80. [PMID: 11202430 DOI: 10.1182/blood.v97.2.579] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
28
|
Singer M, Stopka T, Siano C, Springer K, Barton G, Khoshnood K, Gorry de Puga A, Heimer R. The social geography of AIDS and hepatitis risk: qualitative approaches for assessing local differences in sterile-syringe access among injection drug users. Am J Public Health 2000; 90:1049-56. [PMID: 10897181 PMCID: PMC1446282 DOI: 10.2105/ajph.90.7.1049] [Citation(s) in RCA: 82] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
While significant gains have been achieved in understanding and reducing AIDS and hepatitis risks among injection drug users (IDUs), it is necessary to move beyond individual-level characteristics to gain a fuller understanding of the impact of social context on risk. In this study, 6 qualitative methods were used in combination with more traditional epidemiologic survey approaches and laboratory bioassay procedures to examine neighborhood differences in access to sterile syringes among IDUs in 3 northeastern cities. These methods consisted of (1) neighborhood-based IDU focus groups to construct social maps of local equipment acquisition and drug use sites; (2) ethnographic descriptions of target neighborhoods; (3) IDU diary keeping on drug use and injection equipment acquisition; (4) ethnographic day visits with IDUs in natural settings; (5) interviews with IDUs about syringe acquisition and collection of syringes for laboratory analysis; and (6) focused field observation and processual interviewing during drug injection. Preliminary findings from each of these methods are reported to illustrate the methods' value in elucidating the impact of local and regional social factors on sterile syringe access.
Collapse
Affiliation(s)
- M Singer
- Hispanic Health Council, Hartford, Conn. 06106, USA.
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Stopka T, Zakova D, Fuchs O, Kubrova O, Blafkova J, Jelinek J, Necas E, Zivny J. Chromatin remodeling gene SMARCA5 is dysregulated in primitive hematopoietic cells of acute leukemia. Leukemia 2000; 14:1247-52. [PMID: 10914549 DOI: 10.1038/sj.leu.2401807] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
We identified a subset of genes involved in chromatin remodeling whose mRNA expression changes in differentiating mouse erythroleukemia (MEL) cells. We furthermore tested their mRNA expression patterns in normal and malignant CD34+ bone marrow cells. SMARCA5, imitation switch gene homologue, was rapidly silenced during in vitro erythroid differentiation of MEL cells whereas it was up-regulated in CD34+ hematopoietic progenitors of acute myeloid leukemia (AML) patients. Moreover, SMARCA5 mRNA levels decreased in AML CD34+ progenitors after the patients achieved complete hematologic remission. We detected high levels of SMARCA5 mRNA in murine bone marrow and spleen and monitored its expression in these hematopoietic tissues during accelerated hematopoiesis following hemolytic anemia induced by phenylhydrazine. SMARCA5 expression levels decreased after the onset of accelerated erythropoiesis. Our data suggest that both in vitro and in vivo induction of differentiation is followed by down-regulation of SMARCA5 expression. In CD34+ AML progenitors over-expression of SMARCA5 may thus dysregulate the genetic program required for normal differentiation.
Collapse
MESH Headings
- Acute Disease
- Anemia, Hemolytic/chemically induced
- Anemia, Hemolytic/metabolism
- Anemia, Hemolytic/pathology
- Animals
- Bone Marrow/metabolism
- Bone Marrow/pathology
- Cell Differentiation/drug effects
- Cell Differentiation/genetics
- Chromatin/metabolism
- DNA Topoisomerases, Type II/biosynthesis
- DNA Topoisomerases, Type II/genetics
- Erythroid Precursor Cells/metabolism
- Erythroid Precursor Cells/pathology
- Gene Expression Profiling
- Gene Expression Regulation, Leukemic
- Hematopoiesis/genetics
- Hematopoietic Stem Cells/metabolism
- Hematopoietic Stem Cells/pathology
- High Mobility Group Proteins/biosynthesis
- High Mobility Group Proteins/genetics
- Humans
- Leukemia, Erythroblastic, Acute/genetics
- Leukemia, Erythroblastic, Acute/metabolism
- Leukemia, Erythroblastic, Acute/pathology
- Leukemia, Myeloid/genetics
- Leukemia, Myeloid/metabolism
- Leukemia, Myeloid/pathology
- Mice
- Mice, Inbred C3H
- Neoplasm Proteins/biosynthesis
- Neoplasm Proteins/genetics
- Neoplastic Stem Cells/metabolism
- Neoplastic Stem Cells/pathology
- Phenylhydrazines/toxicity
- RNA, Messenger/biosynthesis
- RNA, Neoplasm/biosynthesis
- Spleen/metabolism
- Spleen/pathology
- Subtraction Technique
- Tumor Cells, Cultured
Collapse
Affiliation(s)
- T Stopka
- Institute of Hematology and Blood Transfusion and Department of Pathophysiology, First Medical Faculty, Charles University, Prague, Czech Republic
| | | | | | | | | | | | | | | |
Collapse
|
30
|
Hassoun H, Pavlovsky M, Mansoor S, Stopka T. Diagnosis of polycythemia vera in an anemic patient. South Med J 2000; 93:710-2. [PMID: 10923962] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Abstract
Criteria proposed by the Polycythemia Vera Study Group (PVSG) as well as several derived algorithms are currently used for the diagnosis of polycythemia vera. Although these guidelines have significantly enhanced diagnostic accuracy, they uniformly consider erythrocytosis as the requisite premise for instigating the subsequent workup. We describe the unusual presentation of a patient with microcytic anemia in whom the diagnosis of polycythemia vera was reached using the PVSG criteria and confirmed by in vitro culture assay of erythroid progenitor cells. This case highlights the usefulness of the PVSG criteria, including the red cell mass determination, for the diagnosis of polycythemia vera even in anemic patients. The roles of spleen red cell pooling and plasma volume expansion as major determinants of this unusual presentation are discussed.
Collapse
Affiliation(s)
- H Hassoun
- Department of Biomedical Research, St Elizabeth's Medical Center of Boston, Tufts University Medical School, Mass 02135, USA
| | | | | | | |
Collapse
|
31
|
Stopka T, Blafkova J, Zakova D, Fuchs O, Cmejla R, Necas E, Jelinek J, Zivny J. Cloning and expression of murine hematopoietic specific chromatin remodeling gene SMARCA5. Exp Hematol 2000. [DOI: 10.1016/s0301-472x(00)00455-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
32
|
Pomyje J, Æivn̋ J, Stopka T, ©imák J, VaÚková H, Necas E. Expression of ANGIOPOIETIN-1, ANGIOPOIETIN-2, and TIE-2 in bone marrow and tumor during growth of experimental melanoma. Exp Hematol 2000. [DOI: 10.1016/s0301-472x(00)00456-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
33
|
Cmejla R, Blafkova J, Stopka T, Zavadil J, Pospisilova D, Mihal V, Petrtylova K, Jelinek J. Ribosomal protein S19 gene mutations in patients with diamond-blackfan anemia and identification of ribosomal protein S19 pseudogenes. Blood Cells Mol Dis 2000; 26:124-32. [PMID: 10753603 DOI: 10.1006/bcmd.2000.0286] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Diamond-Blackfan anemia (DBA) is a rare congenital pure red cell hypoplasia characterized by a selective defect of erythropoiesis with a normochromic macrocytic anemia and reticulocytopenia often accompanied by various congenital anomalies. The critical region responsible for the pathogenesis of DBA has been mapped in some patients to chromosome 19q13.2 (P Gustavsson, E Garelli, N Draptchinskaia, et al. Am. J. Hum. Genet. 63:1388-1395, 1998) and the gene encoding ribosomal protein S19 (RPS19) is believed to be the candidate gene. Here we present molecular analysis of the RPS19 gene in DBA patients from the Czech National DBA Registry. We found that the RPS19 gene was mutated in 25% (5/20) of DBA patients (insertion, deletion, and point mutations, but no nonsense or splice site mutations). Point mutations were localized to hot spots defined by Willig (TN Willig, N Draptchinskaia, I Dianzani, et al. Blood 94:4294-4306, 1999). Moreover, we describe two processed RPS19 pseudogenes, which were not expressed. Possible models of the DBA pathogenesis in the view of RPS19 mutations are discussed.
Collapse
Affiliation(s)
- R Cmejla
- Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
| | | | | | | | | | | | | | | |
Collapse
|
34
|
Stopka T, Zivny JH, Goldwasser E, Prchal JF, Necas E, Prchal JT. Guinea pig serum erythropoietin (EPO) selectively stimulates guinea pig erythroid progenitors: human or mouse erythroid progenitors do not form erythroid burst-forming unit colonies in response to guinea pig serum EPO. Exp Hematol 1998; 26:910-4. [PMID: 9694513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Erythropoietin (EPO) is the primary regulator of mammalian erythropoiesis, providing a proliferative and differentiative signal to the early EPO-responsive erythroid progenitors, burst-forming unit-erythroid (BFU-E) and colony-forming unit-erythroid, as well as to later EPO-responsive erythroid progenitors. EPO is secreted by the kidney in response to hypoxia and anemia. There is an extensive biological crossreactivity between human EPO and the EPOs of other mammals. Necas et al. have reported that this crossreactivity may not include the guinea pig (Cavia porcelllus). Because the specificity of the guinea pig's erythropoietic responses may be of biological significance, we compared guinea pig hypoxic serum with mouse (m) and human (h) recombinant (r) EPOs for their ability to induce erythroid progenitor proliferation and differentiation in semisolid cultures. Guinea pig bone marrow mononuclear cells (BMMCs) formed BFU-E colonies in response to guinea pig hypoxic serum, rhEPO, or rmEPO in a dose-dependent fashion. Neither human nor mouse BMMCs responded to guinea pig hypoxic serum; however, guinea pig hypoxic serum exerted no inhibitory effect on human or mouse in vitro erythroid differentiation in the presence of rhEPO or rmEPO. The intensity of the EPO band on Western blotting analysis of guinea pig hypoxic serum was significantly greater than in nonhypoxic serum. This suggests that guinea pig erythropoiesis is mediated by EPO and stimulated by hypoxia in a fashion similar to that observed in human and mouse erythropoiesis. Furthermore, guinea pig EPO did not stimulate human or mouse erythroid differentiation in vitro, whereas guinea pig erythroid progenitors could be stimulated by human or mouse EPO, suggesting structural differences in guinea pig EPO and EPO receptor (EPOR) compared with human or mouse EPO and EPOR. These differences probably evolved after the guinea pig's ancestors diverged from myomorph rodents. Further characterization of the guinea pig EPO and EPOR should facilitate our understanding of the interaction between EPO and EPOR.
Collapse
Affiliation(s)
- T Stopka
- Division of Hematology/Oncology, University of Alabama at Birmingham and VAH, 35294, USA
| | | | | | | | | | | |
Collapse
|
35
|
Julian BA, Brantley RR, Barker CV, Stopka T, Gaston RS, Curtis JJ, Lee JY, Prchal JT. Losartan, an angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis. J Am Soc Nephrol 1998; 9:1104-8. [PMID: 9621296 DOI: 10.1681/asn.v961104] [Citation(s) in RCA: 71] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
The mechanism by which angiotensin-converting enzyme inhibitors reduce red cell mass in renal transplant recipients with erythrocytosis is unclear. To examine the role of angiotensin II in this disorder, losartan (a competitive antagonist of the angiotensin II type 1 [AT1] receptor) was administered to 23 patients with erythrocytosis. Fourteen patients took 25 mg/d for 8 wk; nine others were treated with 50 mg/d for 8 wk. Hematocrit decreased from 0.527 +/- 0.027 to 0.487 +/- 0.045 after 8 wk (P < 0.01)--by at least 0.04 in 19 patients. Decrement in hematocrit in the initial 8 wk of therapy was significantly greater in patients administered 50 mg/d than in patients on 25 mg/d. Twelve of 14 patients initially treated with 25 mg/d showed a small change in hematocrit; the dose was increased to 50 mg/d for 8 more wk. Hematocrit decreased from 0.528 +/- 0.030 before losartan treatment to 0.483 +/- 0.055 after 16 wk (P < 0.01). After therapy, serum erythropoietin significantly decreased in eight patients with elevated baseline levels, but not in 15 patients with normal baseline levels; however, hematocrit significantly decreased in both groups. Losartan was withdrawn in 16 patients; hematocrit increased from 0.440 +/- 0.057 to 0.495 +/- 0.049 after 8.9 +/- 7.5 wk (P < 0.001), without change in serum erythropoietin. Thus, specific blockade of AT1 receptors inhibited erythropoiesis, suggesting a pathogenic role for angiotensin II in posttransplant erythrocytosis.
Collapse
Affiliation(s)
- B A Julian
- Department of Medicine, University of Alabama at Birmingham, USA
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Stopka T, Zivny JH, Stopkova P, Prchal JF, Prchal JT. Human hematopoietic progenitors express erythropoietin. Blood 1998; 91:3766-72. [PMID: 9573013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Erythropoietin (EPO) is a factor essential for erythroid cell proliferation, differentiation, and survival. The production of EPO by the kidneys in response to hypoxia and anemia is well documented. To determine whether EPO is also produced by hematopoietic cells, we analyzed the expression of EPO in normal human hematopoietic progenitors and in their progeny. Undifferentiated CD34(+)lin- hematopoietic progenitors do not have detectable EPO mRNA. Differentiating CD34(+) cells that are stimulated with recombinant human EPO in serum-free liquid cultures express both EPO and EPO receptor (EPOR). Because CD34(+) cells represent a heterogeneous cell population, we analyzed individual burst-forming units-erythroid (BFU-E) and nonerythroid colony-forming unit-granulocyte-macrophage colonies for EPO mRNA. Only BFU-E colonies were positive for EPO mRNA. Lysates from pooled BFU-E colonies stained positively for EPO by immunoblotting. To further confirm the intrinsic nature of erythroid EPO, we replaced extrinsic EPO in erythroid colony cultures with EPO-mimicking peptide (EMP). We show EPO expression in the EMP-stimulated BFU-Es at both mRNA and protein levels. Stimulation of bone marrow mononuclear cells (BMMCs) with EMP upregulated EPO expression. Furthermore, we found EPO and EPOR mRNAs as well as EPO protein in K562 cells, a human erythroleukemia cell line. Stimulation of K562 cells with EMP upregulated EPO expression. We suggest that EPO of erythroid origin may have a role in the regulation of erythropoiesis.
Collapse
MESH Headings
- Adult
- Antigens, CD34/analysis
- Base Sequence
- Carcinoma, Hepatocellular/pathology
- Cell Hypoxia/genetics
- Cells, Cultured
- Cobalt/pharmacology
- Culture Media, Serum-Free
- Enzyme-Linked Immunosorbent Assay
- Erythroid Precursor Cells/drug effects
- Erythroid Precursor Cells/metabolism
- Erythropoiesis/drug effects
- Erythropoiesis/genetics
- Erythropoietin/biosynthesis
- Erythropoietin/genetics
- Gene Expression Regulation/drug effects
- Hematopoietic Stem Cells/drug effects
- Hematopoietic Stem Cells/metabolism
- Humans
- Leukemia, Erythroblastic, Acute/pathology
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology
- Liver Neoplasms/pathology
- Molecular Sequence Data
- Peptides/pharmacology
- RNA, Messenger/biosynthesis
- Receptors, Erythropoietin/biosynthesis
- Receptors, Erythropoietin/genetics
- Tumor Cells, Cultured
Collapse
Affiliation(s)
- T Stopka
- Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA
| | | | | | | | | |
Collapse
|
37
|
Abstract
Angiotensin II exerts a mitogenic effect in several in vitro models, but a direct effect on erythroid progenitors has not been documented. Angiotensin-converting enzyme inhibitors and losartan, an angiotensin II type 1 receptor (AT1) antagonist, ameliorate posttransplant erythrocytosis, without altering serum erythropoietin levels. We studied erythroid differentiation and the effect of angiotensin II on proliferation of erythroid progenitors by culturing CD34+ hematopoietic progenitor cells in liquid serum-free medium favoring growth of erythroid precursors. Aliquots of cells were collected every third day, and were used for RNA preparation. AT1 mRNA was detected after 6 d. In these same samples, erythroid-specific mRNA (erythropoietin receptor) was also detected. AT1 protein was detected in 7-d-old burst-forming units-erythroid colonies by Western blotting. The CD34+ cell liquid cultures were used to incubate erythroid precursors with angiotensin II from days 6-9. After incubation, cells were transferred to semisolid medium and cultured with erythropoietin. Angiotensin II increased proliferation of early erythroid progenitors, defined as increased numbers of burst-forming units-erythroid colonies. Losartan completely abolished this stimulatory effect of angiotensin II. Moreover, we observed increased numbers of erythroid progenitors in the peripheral blood of posttransplant erythrocytosis patients. Thus, activation of AT1 with angiotensin II enhances erythropoietin-stimulated erythroid proliferation in vitro. A putative defect in the angiotensin II/AT1 pathway may contribute to the pathogenesis of posttransplant erythrocytosis.
Collapse
Affiliation(s)
- M Mrug
- Division of Hematology/Oncology, University of Alabama, Birmingham 35294, USA
| | | | | | | | | |
Collapse
|
38
|
Kralovics R, Indrak K, Stopka T, Berman BW, Prchal JF, Prchal JT. Two new EPO receptor mutations: truncated EPO receptors are most frequently associated with primary familial and congenital polycythemias. Blood 1997; 90:2057-61. [PMID: 9292543] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Primary polycythemias are caused by an acquired or inborn mutation affecting hematopoietic/erythroid progenitors that results in an abnormal response to hematopoietic cytokines. Primary familial and congenital polycythemia (PFCP; also known as familial erythrocytosis) is characterized by elevated red blood cell mass, low serum erythropoietin (EPO) level, normal oxygen affinity of hemoglobin, and typically autosomal dominant inheritance. In this study we screened for mutations in the cytoplasmic domain of the EPO receptor (EPOR; exons 7 and 8 of the EPOR gene) in 27 unrelated subjects with primary or unidentified polycythemia. Two new EPOR mutations were found, which lead to truncation of the EPOR similarly to previously described mutations in PFCP subjects. The first is a 7-bp deletion (del5985-5991) found in a Caucasian family from Ohio. The second mutation (5967insT) was found in a Caucasian family from the Czech Republic. In both cases the EPO dose responses of the erythroid progenitors of the affected subjects were examined to confirm the diagnosis of PFCP. In one of these families, the in vitro behavior of erythroid progenitors in serum-containing cultures without the addition of EPO mimicked the behavior of polycythemia vera progenitors; however, we show that antibodies against either EPO or the EPOR distinguish the in vitro growth abnormality of polycythemia vera erythroid progenitors from that seen in this particular PFCP family. We conclude that PFCP is a disorder that appears to be associated in some families with EPOR mutations. So far, most of the described EPOR mutations (6 out of 8) associated with PFCP result in an absence of the C-terminal negative regulatory domain of the receptor.
Collapse
Affiliation(s)
- R Kralovics
- Division of Hematology/Oncology, University of Alabama, Birmingham 35294, USA
| | | | | | | | | | | |
Collapse
|